We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Breakthrough Drug May Help to Reverse Spinal Damage

By LabMedica International staff writers
Posted on 15 Dec 2014
Print article
Image: Scientists have created a drug that helps nerve fibers cross scar tissue barriers after spinal cord injury (Photo courtesy of the NIH).
Image: Scientists have created a drug that helps nerve fibers cross scar tissue barriers after spinal cord injury (Photo courtesy of the NIH).
Injections of a new drug may partially relieve paralyzing spinal cord injuries, based on new findings from experiments performed in lab rats.

The new study, which was partly funded by the US National Institutes of Health (NIH; Bethesda, MD, USA), demonstrated how basic laboratory research can lead to new therapy options. “We’re very excited at the possibility that millions of people could, one day, regain movements lost during spinal cord injuries,” said Jerry Silver, PhD, professor of neurosciences, Case Western Reserve University School of Medicine (Cleveland, OH, USA), and a senior investigator of the study published December 3, 2014, in the journal Nature.

Every year, tens of thousands of people are paralyzed by spinal cord injuries. The injuries press and sever the long axons of spinal cord nerve cells, blocking communication between the brain and the body and resulting in paralysis below the injury. Using intuition, Bradley Lang, PhD, the lead author of the study and a graduate student in Dr. Silver’s lab, came up with the strategy of designing a drug that would help axons regenerate without having to touch the healing spinal cord, as current treatments may require. “Originally this was just a side project we brainstormed in the lab,” said Dr. Lang.

After spinal cord injury, axons try to cross the injury site and reconnect with other cells but are stymied by scarring that forms after the injury. Earlier research suggested their movements are blocked when the protein tyrosine phosphatase sigma (PTP sigma), an enzyme found in axons, interacts with chondroitin sulfate proteoglycans, a family of sugary proteins that fill the scars.

Dr. Lang and his colleagues designed a drug called intracellular sigma peptide (ISP) to block the enzyme and facilitate the drug’s entry into the brain and spinal cord. Injections of the drug under the skin of paralyzed rats close to the damaged site partially restored axon growth and improved movements and bladder functions. “There are currently no drug therapies available that improve the very limited natural recovery from spinal cord injuries that patients experience,” said Lyn Jakeman, PhD, a program director at the NIH’s National Institute of Neurological Disorders and Stroke (Bethesda, MD, USA). “This is a great step towards identifying a novel agent for helping people recover.”

At first, the objective of the research was to determine precisely how interactions between PTP sigma and chondroitin sulfate proteoglycans prevent axon growth. Drugs were designed to mimic the shape of a key part of PTP sigma, called the wedge. Different designs were evaluated on neurons grown in petri dishes alongside impenetrable barriers of proteoglycans. Treatment with ISP freed axon growth. “It was amazing. The axons kept growing and growing,” said Dr. Silver.

The scientists next tested the potential of the drug on a rat model of spinal cord injury. For seven weeks they injected rats with the drug or a placebo near the site of injury. A few weeks later the rats that received the drug showed improvements in walking and urinating while the placebo treatments had no effect. The findings suggested the drug passed into the brain and spinal cord.

When the researchers looked at the spinal cords under a microscope they found that the drug triggered sprouting of axons that use the neurochemical serotonin to communicate. The sprouting axons were seen below the injury site. Treating some of the lab rats with a blocker of serotonin communication partially reversed the advantageous effects of ISP injections, suggesting the newly growing axons helped the rats recover.

The ISP drug did not cause spinal cord axons known to control movements to cross the scar and reconnect with brain neurons above the injury site. Dr. Silver and his colleagues think this means the ISP-induced sprouting helped the rats recover by increasing the signal sent by the few remaining intact axons. “This is very promising. We now have an agent that may work alone or in combination with other treatments to improve the lives of many,” concluded Dr. Silver. He and his colleagues are looking to evaluate the ISP drug in preclinical trials.

Related Links:

Case Western Reserve University School of Medicine
National Institute of Neurological Disorders and Stroke


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.